Welcome to our dedicated page for Pavmed news (Ticker: PAVMZ), a resource for investors and traders seeking the latest updates and insights on Pavmed stock.
PAVmed Inc. Series Z Warrant (symbol: PAVMZ) is a diversified commercial-stage medical technology company focused on developing innovative medical devices, diagnostics, and digital health solutions. Led by accomplished medical device entrepreneurs, the company aims to address unmet clinical needs by swiftly advancing a pipeline of cutting-edge products. PAVmed operates in three primary segments: Diagnostics, Medical Devices, and Digital Health. Its flagship products include EsoGuard, esocheck, and the Veris Cancer Care Platform, offering revolutionary solutions for cancer prevention and personalized care.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) announced that Aster Angagaw has joined the Board of Directors of its subsidiary, Lucid Diagnostics. Angagaw brings extensive experience in healthcare and business transformation, previously serving prominent roles at Owens & Minor and ServiceMaster Brands. PAVmed's chairman, Lishan Aklog, emphasized her expertise will enhance Lucid's growth strategy in precancer screening technologies. This appointment is expected to strengthen Lucid's leadership as it aims for long-term expansion.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) announced a business update conference call scheduled for August 12, 2021, at 4:30 PM EDT. CEO Lishan Aklog will discuss near-term milestones and the growth strategy, while CFO Dennis McGrath will present the second quarter 2021 financial results. Interested parties can join by phone or via webcast on the company’s website. PAVmed focuses on developing differentiated medical technologies, addressing unmet needs across several clinical areas, with subsidiaries such as Lucid Diagnostics and Veris Health.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) has appointed medical diagnostics pioneer Stanley N. Lapidus as Vice Chairman of its subsidiary, Lucid Diagnostics Inc. Lapidus, a former CEO of Exact Sciences, is known for his contributions to early cancer detection technologies. He aims to promote the EsoGuard test for early detection of esophageal cancer. PAVmed's management highlights Lapidus’s strategic input in ongoing initiatives, reinforcing Lucid's long-term growth plans. PAVmed continues to innovate with a broad product pipeline targeting unmet clinical needs.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) announced a partnership through its subsidiary, Lucid Diagnostics Inc., with UpScriptHealth to launch the EsoGuard Telemedicine Program. This program aims to provide chronic heartburn patients with remote evaluations and referrals for the EsoGuard Esophageal DNA Test. Initially launching in Arizona, the program is expected to expand nationwide, enhancing patient access to early detection of esophageal cancer. CEO Lishan Aklog emphasizes the significance of addressing healthcare gaps and promoting awareness regarding chronic heartburn's link to esophageal cancer.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) appoints Tim Baxter, former President of Samsung Electronics North America, to its Board of Directors, enhancing its leadership with a seasoned technology expert. Baxter, who will chair the Nomination Committee, brings extensive experience in innovation and business strategy, with a focus on technology integration in healthcare. Concurrently, David Battleman and David Weild IV are stepping down from the Board. This change aims to leverage Baxter's expertise to drive growth through PAVmed's digital health initiatives and products aimed at improving patient care.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) announced the completion of European IVDD CE Mark certification for its EsoGuard® Esophageal DNA Test through its subsidiary, Lucid Diagnostics Inc. This certification allows EsoGuard to be marketed across CE Mark European nations, including the EU and Switzerland. EsoGuard is the first molecular diagnostic test for early detection of esophageal precancer and cancer, proving highly accurate in a study of 408 patients. PAVmed's CEO anticipates Europe as a significant market due to the prevalence of chronic heartburn and esophageal cancer.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) has launched a new subsidiary, Veris Health Inc., which has acquired Oncodisc Inc., an oncology digital health company. This acquisition aims to enhance personalized cancer care through a novel implantable vascular access port with biologic sensors and a digital health platform. Veris is targeting a $2 to $3 billion market, focusing on remote patient monitoring and subscription-based revenue models. The management anticipates significant synergies with existing infrastructure and aims for FDA clearance of its products by mid-2022.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) announces that its subsidiary, Lucid Diagnostics, has received CE Mark certification for the EsoCheck® Esophageal Cell Collection Device. Effective May 24, 2021, this certification allows EsoCheck to be marketed in CE Mark countries, including the EU and the UK until July 1, 2023. EsoCheck is a unique, FDA-cleared device enabling non-invasive sampling of esophageal cells, aimed at early detection of esophageal cancer. The company plans to initiate a commercial launch in select European markets in the near future.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) has received CE Mark certification for its CarpX® device, enabling its marketing in European countries. The certification, issued by TÜV Rhineland LGA Products GMBH, confirms the device's compliance with European medical device regulations, effective May 24, 2021. CarpX is a minimally invasive tool for treating carpal tunnel syndrome, which promises reduced recovery times. The company anticipates a robust market opportunity in Europe, matching that of the U.S. as it moves towards a commercial launch.
FAQ
What is the current stock price of Pavmed (PAVMZ)?
What is PAVmed Inc.'s main focus?
What are some of PAVmed Inc.'s key products?
Who leads PAVmed Inc. Series Z Warrant?
In what segments does PAVmed Inc. operate?
What sets PAVmed Inc. apart from other medical technology companies?
